This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Oncothyreon: A Failed Drug Autopsy Performed By A Short Seller

Stocks in this article: ONTY

We spent a lot of money but the advice given to us by these consultants was never definitive or convincing. Some of it was just wrong. In the end, the Northfield study failed. My firm's short bet was right but not because some consultant told us what to do. Instead, the Northfield study failed because its drug didn't work, which was clear from prior studies and a good understanding of its mechanism. Having a good knowledge of bio-statistics is helpful in biotech investing, but simpler analyses are often better than more complex models.

Prior clinical data is important. Don't ignore (especially when the data are bad.)

This should go without saying, but the scant phase II data supporting the decision to move Stimuvax into a much larger phase III lung cancer trial was pathetic. Oncothyreon bulls glossed over this red flag because the "phase III trial was taking longer than expected" or because "Merck KGaA knew something." Nope. Bad phase II data leads to phase III data. Investors who ignore this rule lose money.

Big Pharma doeesn't always know best.

Oncothyreon bulls believed in Stimuvax because they saw Merck KGaA's involvement as a big credibility booster. Stop thinking that way. Pharmaceutical companies are run by people like you and me, and they make mistakes. In fact, Big Pharma execs make a lot of mistakes. The average investment in R&D results in loss of capital to drug companies. The Stimuvax program is an embarrassment to Merck KGaA and was an awful idea. These things happen, people get fired, companies are restructured and life goes on. Don't be the victim of a large company's afterthoughts.

Shkreli has no position in Oncothyreon.

Martin Shkreli is the managing member of MSMB Capital, a New York-based hedge-fund and private-equity firm focused on health care. He is also president and founder of Retrophin, a biotechnology company that develops treatments for rare and severe diseases. Shkreli has spent his career in the hedge-fund industry, previously in roles with Intrepid Capital Management and Cramer Berkowitz & Co. Shkreli lives in New York City and received a BBA in finance from Baruch College.
2 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs